Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy
about
Pharmacological modulation of the retinal unfolded protein response in Bardet-Biedl syndrome reduces apoptosis and preserves light detection abilityEndoplasmic reticulum stress and oxidative stress in cell fate decision and human disease.Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: a retrospective study with implications for trial design.Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes.Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesisMechanistic Insight into the Reactivation of BCAII Enzyme from Denatured and Molten Globule States by Eukaryotic Ribosomes and Domain V rRNAsRNA-binding proteins in neurodegenerative disease: TDP-43 and beyond.PABPN1 gene therapy for oculopharyngeal muscular dystrophyThe various facets of the protein-folding activity of the ribosome.Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity.PABPN1: molecular function and muscle disease.Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).The double life of the ribosome: When its protein folding activity supports prion propagation.Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation.The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition.
P2860
Q28591411-5319C574-7E4D-45F8-BC1F-091CD261CD4BQ33828303-16FCF7C0-FB70-45A6-892C-92370F9D9D01Q35164440-89EE5452-B38F-4E44-B86D-A83301AE2200Q35180639-027604AF-83B4-43EA-B284-9CB1EBD8BC12Q35224241-E024524B-5772-440F-9584-5CD25157D314Q35995635-6DDDCDB1-3C39-4788-B0ED-72822AB34548Q37155206-3B24B213-FE33-44E2-969E-168E275640A5Q37737844-52FF391E-E14C-486D-851C-9D5DCF1FDC30Q37875025-3FBCEFD6-CED7-4EB2-9AD1-CC5D02EEDB20Q37952582-ECC7C178-34E6-46BE-9AC2-3E8E6C5C1408Q38100286-EF9794CF-60EF-4BD4-8291-FB9FE5679DD3Q38628274-A42F1E71-0399-4C0B-B525-FC22C09F0608Q39211074-C1A73EA5-F103-400C-BC7A-F5340228060AQ39385280-575A6675-BC9A-42EB-B377-F1896DB8CF5AQ41355901-29EBE3DC-237A-48ED-92AD-5C54D7EF3D7C
P2860
Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@ast
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@en
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@nl
type
label
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@ast
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@en
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@nl
prefLabel
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@ast
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@en
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@nl
P2093
P2860
P50
P356
P1476
Antiprion drugs 6-aminophenant ...... opharyngeal muscular dystrophy
@en
P2093
Aymeric Chartier
Cécile Voisset
Elisabeth Schwarz
Hervé Galons
Martine Simonelig
Nicolas Barbezier
P2860
P356
10.1002/EMMM.201000109
P577
2011-01-01T00:00:00Z